Clinical trials: Aromatase Inhibitor
Breast Cancer, Joint Pain
Glucosamine and Chondroitin for Aromatase Inhibitor Induced Joint Symptoms in Women With Breast Cancer
Investigators are hoping to learn if glucosamine with chondroitin can help relieve joint pain/stiffness associated with aromatase inhibitors.
- Trial name
- NCT00691678
- Testing
- Chondroitin, Glucosamine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Dawn L. Hershman
Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy
Evaluating the Impact of Baduanjin Exercise Intervention on Quality of Life in Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy
A 12-week randomized controlled trail was conducted in 72 Chinese breast cancer survivors who had received aromatase inhibitors treatment for more than 6 months.
- Trial name
- NCT03162133
- Testing
- Baduanjin exercise
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer, Medication Adherence
SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors
The purpose of this study is to determine whether weekly SMS reminders are effective in improving medication adherence of adjuvant aromatase inhibitors in women with breast cancer.
- Trial name
- NCT02524548
- Testing
- SMS reminder
- Where
- 2 sites in Singapore
- Volunteers
- 244 people
- Sponsor
- National University of Singapore
Breast Cancer
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in…
- Trial name
- CTIBL (NCT00712985)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Advanced or Metastatic ER+ Breast Cancer
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with…
- Trial name
- NCT02734615
- Testing
- LSZ102, LEE011, BYL719
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT01160718
- Testing
- fulvestrant, selumetinib
- Where
- 17 sites in Belgium, Switzerland
- Volunteers
- 46 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, Osteoporosis
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
RATIONALE: Zoledronate may reduce bone loss in patients receiving letrozole for breast cancer. PURPOSE: This clinical trial is studying how well zoledronate works in treating osteopenia or osteoporosis in postmenopausal women…
- Trial name
- NCT00436917
- Testing
- zoledronic acid, Letrozole as adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Breast Neoplasm Female
Web-Base App To Improve Aromatase Inhibitor Adherence
The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of the initial prescription to an aromatase inhibitor to improve communication and management of treatment-related…
- Trial name
- AETAPP (NCT02957526)
- Testing
- Prompts to report symptoms via study app, Clinical Alerts
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- University of Tennessee
IVF
RIOTC: Reducing the Impact of Ovarian Stimulation. Novel Approaches to Luteal Support in IVF-Study 2
The goal of the randomised controlled study (RCT) is to identify novel strategies that can improve the luteal phase endocrinology after ovarian stimulation, with the aim of using less or no luteal support in IVF while making the…
- Trial name
- RIOTC (NCT04524026)
- Testing
- Letrozole 5 mg
- Where
- 2 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- Nicholas Macklon
Breast Cancer
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer…
- Trial name
- NCT00767520
- Testing
- Exemestane + Dasatinib
- Where
- 21 sites in United States, Czechia and 6 more
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients
To compare the efficacy and safety of neoadjuvant aromatase inhibitor plus ovarian suppression with chemotherapy in premenopausal patients with hormone receptor-positive breast cancer.
- Trial name
- COMPETE (NCT02532400)
- Testing
- Neoadjuvant endocrine therapy, Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Ruijin Hospital
Breast Cancer
Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study
In 2005, the EBCIG demonstrated the efficacy of tamoxifen in improving overall survival in hormone receptor positive breast cancers.
- Trial name
- AIMS (NCT00653718)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Gestational Trophoblastic Disease
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)
- Trial name
- NCT05203562
- Testing
- Suction evacuation, Letrozole tablets
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Zagazig University
Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00382070
- Testing
- Letrozole
- Where
- 806 sites in United States, Canada and 1 more
- Volunteers
- 3,966 people
- Sponsor
- NSABP Foundation Inc
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Cancer, Menopause
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
Aromatase inhibitor therapy is in France the adjuvant reference treatment for postmenopausal women with early-stage breast cancer. This treatment induces bone loss and a higher risk of fractures.
- Conditions
- Breast Cancer, Menopause, Osteopenia
- Trial name
- RISAROS (NCT00859703)
- Testing
- Risedronate
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer
Comparative Effectiveness of Acupuncture and Nonsteroidal Anti-inflammatory Drugs for the Management of Aromatase Inhibitor Induced Arthralgia Among Breast Cancer Survivors
Hormone therapy is used to treat women with hormone receptor-positive breast cancer and aromatase inhibitor (AI) is administered after menopause.
- Trial name
- NCT04511832
- Testing
- Diclofenac
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- China Medical University Hospital
Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment with Focus on Mechanisms of Resistance to Endocrine Treatment (fulvestrant/aromatase inhibitors) in Patients With Advanced…
- Trial name
- ABC-SE (NCT02958852)
- Testing
- Letrozole, Letrozole and atorvastatin, Fulvestrant
- Where
- Sweden
- Volunteers
- 126 people
- Sponsor
- Lund University Hospital
ER+ Breast Cancer, Breast Cancer
Alcohol and Breast Cancer (ABC) Trial
This research study is a pilot study, which is the first time investigators are examining the effect of light alcohol consumption on sex hormones among postmenopausal women with estrogen receptor-positive (ER+) breast cancer…
- Conditions
- ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
- Trial name
- NCT05423730
- Testing
- White Wine, Grape Juice
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Beth Israel Deaconess Medical Center